You are here

U.S. Hepatitis Trial Put on Hold

Potential liver problems cited (July 25)

The FDA has placed a partial clinical hold on an ongoing phase II U.S. study of VX-135, a nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor, because of possible liver problems.

The partial hold follows the observation of reversible elevated liver enzymes in patients receiving 400 mg of VX-135 in combination with ribavirin in a phase II study in Europe.

The hold prevents evaluation of a 200-mg dose of VX-135 in the U.S. study. Evaluation of a 100-mg dose of VX-135 in combination with ribavirin as part of the 12-week phase II study in the U.S. is continuing as planned.

The compound’s developer (Vertex Pharmaceuticals) currently markets the leading hepatitis C drug, Incivek (telaprevir). To provide high cure rates, however, that treatment must be taken with injected interferon, which is difficult to tolerate.

Sources: Vertex Pharmaceuticals; July 25, 2013; and Reuters; July 25, 2013.

Recent Headlines

Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
But a ‘Serendipitous’ Finding Could Provide a Solution
New Drug Could Make Ears “Young” Again
DNA Changes May Help Predict Women at Risk
Finding Could Spur New Targeted Treatments